Manipal Academy of Higher Education

Impressions@MAHE
Manipal College of Pharmaceutical Sciences,
Manipal Theses and Dissertations

MAHE Student Work

Winter 1-4-2019

Comparison of treatment regimens in Organophosphate and
Carbamate poisoning in a tertiary care hospital-A Retrospective
Analysis
Girish P. Thunga Dr

Follow this and additional works at: https://impressions.manipal.edu/mcops
Part of the Pharmacy and Pharmaceutical Sciences Commons

COMPARISON OF TREATMENT REGIMENS IN
ORGANOPHOSPHATE AND CARBAMATE POISONING IN A
TERTIARY CARE HOSPITAL-: A RETROSPECTIVE ANALYSIS
A Project Report Submitted to
MANIPAL ACADEMY OF HIGHER EDUCATION

In partial fulfilment for the degree of Doctor of Pharmacy (Pharm D)

Submitted by

B. SHRIKAR REDDY

TENY GRACE SKARIA

(Reg No: 130614021)

(Reg No: 130614024)
Pharm D 5th Year

Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education, Manipal.

April 2018

Under the guidance of
GUIDE
Dr. Girish Thunga, M.Pharm, PhD
Assistant Professor (Selection Grade)
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education
Manipal-576104, Karnataka.

This is to certify that this project report entitled, “Comparison of treatment regimens in Organophosphate
and Carbamate poisoning in a tertiary care hospital-A Retrospective Analysis” by Mr. B Shrikar
Reddy and Ms. Teny Grace Skaria for the completion of 5th year Pharm.D comprises of the bonafide work
done by them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and
Kasturba Hospital, Manipal under the guidance of Dr. Girish Thunga, M.Pharm, PhD, Assistant Professor
(Selection Grade), Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal.
I recommend this piece of work for acceptance for the partial fulfilment on the completion of the 5th year
Pharm.D program of the Manipal Academy of Higher Education, Manipal for the Academic year 2017-2018.

Place: Manipal

Dr.Girish Thunga, M.Pharm, PhD

Date:

Assistant Professor, (Selection Grade)
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education,
Manipal – 576104 , Karnataka.

This is to certify that this project report entitled, “Comparison of treatment regimens in Organophosphate
and Carbamate poisoning in a tertiary care hospital-A Retrospective Analysis” by Mr.B Shrikar Reddy
and Ms. Teny Grace Skaria for the completion of 5th year Pharm.D comprises of the bonafide work done by
them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and Kasturba
Hospital, Manipal under the guidance of Dr. Girish Thunga, M.Pharm, PhD, Assistant Professor (Selection
Grade), Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal.
I recommend this piece of work for acceptance for the partial fulfilment on the completion of the 5th year
Pharm.D program of the Manipal Academy of Higher Education, Manipal for the Academic year 2017-2018.

Place: Manipal

Dr. Mahadev Rao, M.Pharm, PhD

Date:

Professor and Head,
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education,
Manipal – 576104, Karnataka.

This is to certify that this project report entitled, “Comparison of treatment regimens in Organophosphate
and Carbamate poisoning in a tertiary care hospital-A Retrospective Analysis” by Mr.B Shrikar Reddy
and Ms. Teny Grace Skaria for the completion of 5th year Pharm.D comprises of the bonafide work done by
them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and Kasturba
Hospital, Manipal under the guidance of Dr. Girish Thunga, M.Pharm, PhD, Assistant Professor (Selection
Grade), Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal.
I recommend this piece of work for acceptance for the partial fulfilment on the completion of the 5th year
Pharm.D program of the Manipal Academy of Higher Education, Manipal for the Academic year 2017-2018.

Place: Manipal

Dr. C. Mallikarjuna Rao, M.Pharm, PhD

Date

Principal,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education,
Manipal-576104, Karnataka.

We hereby declare that the project entitled “Comparison of treatment regimens in Organophosphate and
Carbamate poisoning in a tertiary care hospital-A Retrospective Analysis” was carried out under the
guidance of Dr. Girish Thunga, M.Pharm, PhD, Assistant Professor (Selection Grade), Department of
Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal. The extent and source of
information derived from the existing literature have been indicated throughout the project work at appropriate
places. The work is original and has not been submitted in part or full for any diploma or degree purpose for
this or any other university.

Place: Manipal
Date:

B Shrikar Reddy
(Reg No: 130614021)

Teny Grace Skaria
(Reg No: 130614024)

ACKNOWLEDGEMENT
We express our utmost gratefulness to the almighty for the blessings throughout this study.
We are extremely thankful to our parents & siblings for giving us the opportunity to carry ourselves forward
and for their inconditional love, care,and support.
The success and final outcome of this project required a lot of guidance and assistance. We are extremely
privileged to have got this all along the completion of this project.
We humbly owe our gratitude and sincere regards to our respected teacher and guide Dr. Girish Thunga,
M.Pharm, PhD, Assistant Professor, Department of Pharmacy Practice, Manipal College of Pharmaceutical
Sciences, Manipal; for his valuable guidance, encouragement, untiring patience and support laid by him
during all stages of our work. His encouragement and fruitful suggestions has enabled to make our work
worthy of presentation.
We would also like to thank Dr Sudha Vidyasagar, Professor and Head of Unit, Department of Medicine,
KMC, for her valuable suggestions and guidance.
We are thankful to Dr. Mahadev Rao, M.Pharm, PhD; Professor and Head, Department of Pharmacy
Practice, Manipal College of Pharmaceutical Sciences, Manipal; for his benevolence and timely consent for
carrying out the study.
We thank our beloved Principal, Dr. C. Mallikarjuna Rao, for providing us with all the facilities to move
forward in our career.
We extend our sincere and heartfelt thanks to Dr. Asha Kamath, Professor and Head, Department of
Statistics, MAHE and Mr Keerthan Rao Y for their valuable support in statistical analysis .We would like to
thank our departmental non-teaching staff Mrs. Asha and Mr. Abhilash for their endless support and
cooperation.
We are very much grateful to our friends Ms. Kankana N Aji, Mr Sujayendra Rao U, Ms Roshni Ann Mathai
and Ms Hina Anjum for their remarkable support during our study.
Our heartfelt thanks to all our friends for supporting us whenever needed.
Special thanks to Medical Records Department Staff of Kasturba Hospital, Manipal who have indirectly
made us capable for successful completion of this study.
Lastly, we offer our regards to all those who supported us in any respect during the completion of the project.

TABLE OF CONTENTS
S. No.

Contents

Page No.

1.

INTRODUCTION

1

2.

NEED FOR STUDY

3

3.

OBJECTIVES

5

4.

METHODOLOGY

7

5.

RESULTS

12

6.

DISCUSSION

26

7.

LIMITATIONS

29

8.

CONCLUSION

31

9.

FUTURE DIRECTIONS

33

10.

BIBLIOGRAPHY

35

11.

APPENDICES

39

LIST OF TABLES
Table No.

Title

Page No.

1.

Categorization of poison according to WHO GHS.

10

2.

Demographic characteristics of OP poisoning patients.

13

3.

List of different OP compounds consumed by the patients.

15

4.

Categories of admission to the emergency unit.

15

5.

Physical examination.

16

6.

Clinical presentation of OP poisoning patients.

16

7.

Primary outcomes in various treatment regimens

18

8.

Secondary outcomes in various treatment regimens.

19

9.

Median, (Q1, Q3) values of ICU days & days of mechanical ventilation

19

across various treatment regimens.
10.

Mean ± SD, Median and (Q1, Q3) values of ATR utilised across

20

various treatment regimens.
11.

Median (Q1, Q3) values of total ATR utilised among various treatment

20

patterns.
12.

Frequency of secondary complication and primary outcomes in patients

22

with intermittent ATR dosing.
13.

Incidence of complications in various treatment groups.

22

14.

Median, (Q1, Q3) values of group with complications to the quantity

23

of poison ingested and pseudocholinesterase levels.
15.

Median, (Q1, Q3) values of group with complications to days of

23

mechanical ventilation and days in ICU.
16.

Frequencies of primary outcomes & secondary complication in the

24

treatment group of ATR alone and ATR + GPR.
17.

Comparison of Median, (Q1, Q3) values in treatment groups of ATR

25

alone & ATR+ GPR with secondary outcomes.
18.

Frequency of aspirational pneumonia and ventilator associated
pneumonia in the group treated with ATR + GPR.

25

LIST OF FIGURES
Figure No:

Title

Page No:

1

Study Overview

9

2

Comparison of occupation with the incidence of op

14

poisoning.
3

Type of Pesticide Consumed (According to WHO

14

GHS Classification of Pesticide).
4

Type of the treatment patterns.

17

5

The outcome with various treatment regimens.

18

6

Scatter plot of the total ATR usage with days of

21

hospitalisation.
7

Intermittent ATR dosing in the subject population

21

8

Patients with ATR alone and ATR+ GPR treatment.

24

LIST OF APPENDICES:

Appendix No.

Title

Page No.

1.

Institutional Ethical Clearance Certificate

40

2

Case Report Form

41

LIST OF ABBREVIATIONS

1. ATR - Atropine
2. ASP - Aspiration Pneumonia
3. CRF – Case Rcord form
4. DAMA - Discharged Against Medical Advice
5. GHS - Globally Harmonized System of Classification and Labelling of Chemicals
6. GPR - Glycopyrrolate
7. HIE - Hypoxic Ishemic Encephalopathy
8. ICU - Intensive Care Unit
9. ICD - International Classification of Diseases ,Tenth Revision
10. IQR - Inter Quartile Range
11. OP - Organophosphate Poisoning
12. PAM - Pralidoxime
13. VAP - Ventilator Associated Pneumonia
14. WHO - World Health Organization

ABSTRACT

Introduction
Organophosphate consumption is a most common form of poisoning in Asian countries such as India and
Srilanka. These compounds being highly lipid soluble they can easily distribute in the tissues and can cross
the blood brain barrier and result in various complications. There is an increased rate of morbidity and
mortality associated with these compounds. Eventhough, ATR is the most widely used antidote, treatment
with PAM and GPR are also noteworthy. However, there are no clear studies stating benefits of individual or
combination of regimens with respect to the outcomes. This study is carried out to compare the efficacy and
safety profile of various treatment regimens of these drugs in our hospital setting.

Objectives
To study the various treatment patterns and outcomes in OP poisoning.

Methodology
A retrospective study conducted in Kasturba Hospital on OP poisoning patients admitted during the year 20122017. Patients were identified through medical records with ICD coding T60.0 corresponding to
organophosphate and carbamate poisoning. Patients’ demographical details, clinical symptoms, treatment and
outcomes were collected in a suitably designed CRF and data was analysed using SPSS 20.

Results
A total of 541 patients were enrolled in the study with a mean age 38.60 ± 15.11years (Mean ± SD). Majority
of the patients were males (70.2%) and have consumed poison with an intention of self-harm (98.3%).
Chlorpyriphos (24.2%) was the most common OP compound consumed in our study. Prescription pattern
showed a majority treated with ATR+PAM (41.22%) followed by ATR alone (30.5%), ATR+PAM+GPR was
used in (20.9%) and ATR+GPR in (7.4%) of the study population. Outcome analysis with respect to treatment
pattern revealed better improvement in subject treated with ATR & PAM (74.9%) compared to other treatment
regimens. Similarly the days of ICU (8.97± 5.85), ventilator days 8.37 ±7.11 and development of
complications (42%) was comparatively less in the group treated with ATR & PAM. The addition of GPR
was not found to be beneficial in any terms of primary or secondary outcomes. Secondary complications have
a significant association with intermittent dosing of ATR, quantity of poison ingested, lower levels of
pseudocholinesterase, duration of ventilation and ICU days.

Conclusion
The treatment analysis revealed combination of ATR & PAM ensured better clinical outcomes in terms of
improvement and development of secondary complications. However, addition of GPR did not improve the
overall outcome of the patients. Secondary complications have a significant association with intermittent
dosing of ATR, quantity of poison ingested, lower levels of pseudocholinesterase, duration of ventilation and
ICU days.

INTRODUCTION
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Introduction
Organophosphate poisoning occupies a major share of poisoning with an intention of self -harm. The number
of organophosphate pesticide intoxications is estimated as high as 3,000,000 per year globally, and the average
deaths about 300,000 per year.(1)
It is one of the major public health issues in Asian countries and India in particular. In developing countries
like India, which rely mostly on agriculture, the ease of availability and extensive use of pesticides in
agriculture and horticulture have made this issue portentous.
OP compounds being highly lipid soluble can easily penetrate gastric mucosa and rapidly distribute to tissues,
they even penetrate the blood brain barrier to act on the CNS system.(2). In case of OP poisoning, the inhibition
of the acetylcholinesterase activity by the phosphorylation of acetylcholinesterase renders the enzyme inactive
thereby, causing the accumulation of acetylcholine at the synapse, limning the cholinergic toxidrome. The
symptoms such as miosis, bronchospasm, increased secretions, vomiting, arrhythmia, fasiculations and
respiratory failure are the result of muscarinic and nicotinic enhanced stimulation.(3)
No quantitative tests were available to analyse the OP compound but the estimation of plasma
butyrylcholinesterase (plasma pseudocholinesterase) levels could be analysed to determine OP poisoning
Atropine (ATR) remains the mainstay in the treatment of OP poisoning with its eminent actions and its ability
to penetrate the CNS. It competitively inhibits muscarinic acetylcholine receptors and prevents the further
stimulation. However, literature reports suggest various dosage regimen of atropine administered by infusion
or intermittent dosing. According to literature more than 30 different dosing regimens of ATR are available
in various combinations of loading dose and infusions.(3)
Generally, the treatment will be continued until the suggestive end-points of having a clear chest on
auscultations, heart rate > 80 bpm, systolic BP > 80 mmHg , dilation of pinpointed pupil and dry axillae are
achieved.(4) Apart from the standard antidotes newer options such as oximes and glycopyrrolate (GPR) can be
considered based on the patient condition.
GPR being a Quaternary Ammonium anticholinergic agent exerts its peripheral antimuscarinic actions and is
two to five times potent than ATR.(5) Recent studies suggest that administration of GPR along with ATR may
improve the efficacy of the treatment.(6) However, effectiveness of GPR in the management of OP poisoning
is not clearly established .(1)
In this regard a retrospective study was performed to study the effectiveness of the various treatment patterns
of OP poisoning in a tertiary care hospital.

2
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NEED FOR THE STUDY
Organophosphate compounds are chemicals being used worldwide as pesticides and for domestic purposes.
Self-poisoning of OP compounds has become a great clinical burden in rural areas of developing countries
and they affect all age groups. There are several factors affecting the increased incidence of poisoning such as
the easy availability, low cost, lack of government policies and knowledge regarding safety issues of pesticide
in users/providers in the developing countries. These are highly toxic compounds capable of causing
respiratory paralysis and cardiac arrest which could be fatal. Though, these are associated with a high rate of
morbidity and mortality, there were only a few studies conducted with respect to treatment pattern and
outcome in OP poisoning.
A systematic review by Le Bouffant et al, reveals that there are more than 30 different dosing regimens(3) in
place and the physician had to administer high dose atropine to attain atropinisation which has led to ATR
toxicity. ATR toxicity leads to longer hospitalisation and associated complications. There are various factors
such as poison load, delayed hospital admission, declining laboratory parameters and initial treatment which
effects the dose of ATR.
GPR a Quaternary Ammonium salt is now being used as an adjunct to atropine in controlling bronchial
secretions has been reported in various studies.(6) Eventhough ATR remains as one of the common antidote in
the management of poisoning, literature review regarding utility of GPR in OP poisoning is still an object of
debate.(1)
With the dearth of literature suggesting the efficacies of various antidotes and comparison of the utilisation of
atropine in these treatment patterns, there is a definite need for the present study to explore the different
treatment regimens and compare their effectiveness in the treatment of OP poisoning.

4
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OBJECTIVES



To observe the general treatment pattern in OP poisoning.



To study the effectiveness of ATR and its combined treatment regimens in the management of OP
poisoning.

6
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METHODOLOGY

Study Site: Kasturba Hospital, Manipal.
Study Design: Retrospective Observational Study (2012-2017)
Study Period: 12 months
Ethical Clearance: Obtained from the Institutional Ethics Committee, Kasturba Hospital, Manipal MAHE.
(Appendix 1)
Sample Size: A total number of 600 subjects diagnosed with Organophosphate and Carbamate poisoning
(2012-2017) were included in the study.
Study Criteria:
Inclusion Criteria: All patients with Organophosphate and Carbamate poisoning admitted to the emergency
ward of Kasturba Hospital.
Exclusion Criteria: Patients with mixed poisoning & paediatric population.
Sources for Data Collection: Patient Case Records.
Materials Used: Case Record Form (CRF). (Appendix 2)
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Operation Modality:

Figure 1. Study Overview
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Identification of Patient: The patients were identified from Medical Records Department with ICD coding
T60.0 belonging to class organophosphate and carbamate poisoning. Data was collected from patients’
medical records.
Collection of Data: The medical records of all organophosphate and carbamate were reviewed and the details
of the patient were entered in a case record form. Demographical details like age, gender, occupation and
social history were noted. Information regarding the presence of any psychological or chronic illness, prehospitalisation period and type of admission were retrieved from the files on a structured pro forma.
The type, route and quantity of the pesticide ingested were collected. The toxicity of each poison type were
categorized according to WHO GHS classification (Table 1). Symptoms of patient present during the
admission, pseudocholinesterase level and reports of lab investigations were recorded at the baseline.
Details regarding the treatment pattern and outcome measures in terms of need for assisted ventilation, days
of hospitalization, complications of poisoning and clinical status were evaluated at the time of discharge.
Table 1. Categorization of Poison according to WHO GHS.(7)
CLASSIFICATION CATEGORY
GHS
CLASSIFICATION

Category 1

ORAL

DERMAL

LD50

Hazard

LD50

Hazard

(mg/kg bw)

Statement

(mg/kg bw)

Statement

<5

Fatal

< 50

Fatal in

If swallowed
Category 2

5-50

Fatal

contact with skin
50-200

if swallowed
Category 3

50-300

Toxic

contact with skin
200-1000

if swallowed
Category 4

300-2000

Harmful

2000-5000

May be harmful
if swallowed

Toxic in
contact with skin

1000-3000

if swallowed
Category 5

Fatal in

Harmful in
contact with skin

2000-5000

May be harmful in
contact with skin
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Analysis of data
Assessing the effectiveness of each treatment pattern: Patients were categorized into 4 treatment pattern,
1. ATR alone.
2. ATR + PAM.
3. ATR + GPR.
4. ATR + PAM + GPR.
Effectiveness of each treatment pattern has been compared with the primary and secondary outcomes. Primary
outcomes were assessed in terms of recovery rate (improved/ unimproved). The patients who have been
discharged against medical advice and the patients expired have been grouped under the unimproved category.
The secondary outcomes were analysed in terms of intubation, days of hospitilization, ICU days, days on
ventilation and percentage of secondary complications developed.
Total ATR administered to the patient has been calculated by adding all the doses from the day of admission
to the day of discharge including the infusion and intermittent dosing. The dosing schedule of ATR was
analysed to understand any association between dosing pattern and overall outcome.
Secondary complications has been assessed with respect to type of atropine dosing, quantity of poison
ingested, pseudocholinesterase levels, days of ventilation and days in ICU.
Outcome measures
Primary outcome: Recovery (Improved/ Unimproved). Unimproved category includes patients discharged
against medical advice and expired patients.
Secondary outcomes: The days of hospitalisation, days on ventilation, days in ICU and development of
secondary complications.
Statistical Analysis:
Demographic characteristics like age, gender, type of compound, clinical features along with treatment pattern
and outcome were analyzed using SPSS 20.0 package. Continuous data was analyzed using mean ± SD and
categorical variables were analyzed using frequency. The median and quartiles values were used to determine
association/significance of data in continuous variables to the nominal factors using Mann-Whitney’s test.
Kruskal-Wallis’s test was analysed for significant differences among categorical variables to continuous
variables. Cross-tabulation by Chi square method was used to determine the significant association of nominal
variables.
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RESULTS
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I.

Demographic Characteristics of OP Poisoning Patients.

During 2012- 2017, a total of 600 patients were admitted to the Emergency Ward of Kasturba Hospital,
Manipal with Organophosphate Poisoning. Among them, 541 patients were enrolled in the study.
The mean age of the study population was found to be 38.60 ± 15.11 years. Gender distribution shows very
large variation between the male and female population in the study, with males being 70.2% and females
29.8%.
Among the study population, n=47(8.7%) patients had a history of smoking. History of alcohol consumption
was found in 25.5% (n = 138) patients, while 6.5% (n = 35) of the patients had alcohol dependence syndrome
.Majority of the cases were found to be Suicidal (98.3%). Psychological illness was found in 79 (14.6%)
patients while 104(19.2%) patients had a chronic illness.
Table 2. Demographic Characteristics of OP Poisoning Patients.
Total number of patients
Patient’s Demographic Characteristics
Mean Age ± SD in years
Male, n(%)
Female, n(%)
Smoking, n(%)
Alcoholic, n(%)
Alcohol Dependent Syndrome, n(%)

N = 541

38.6 ±15.61
380(70.2%)
161(29.8%)
47(8.7%)
138(25.5%)
35(6.5%)

Exposure
Suicidal, n(%)
Accidental, n(%)
Homicidal, n(%)

532(98.3%)
7(1.3%)
2(0.4%)

Comorbidities
Psychological illness, n(%)
Chronic illness, n(%)
No comorbidities, n(%)
II.

79(14.6%)
104(19.2%)
358(66.2%)

Occupation and OP Poisoning.

The study population comprised a majority of daily wages workers 152 (28.1%) followed by agriculturalists
133 (24.6%) and household 111 (20.5%).

13

Fig 2. Comparison of occupation with the incidence of op poisoning.
III.

Type of Pesticide consumed.

There were 12 op compounds found in our study, they were classified according to the WHO Globally
Harmonized System of Classification and Labelling of Chemicals (GHS).Among the study population
Category 3 was found to be most common(37.7%).

Fig 3. Type of Pesticide Consumed (According to WHO GHS Classification of Pesticide).
Classification of Poison based on the generic name
Among the different Organophosphate Poisoning compounds consumed chlorpyriphos contributes 131
(24.2%) of the total OP admissions during the study while in 207 (38.3%) the poison ingested was not
specified.
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Table 3. List of different OP Compounds consumed by the patients.
Poison Type

IV.

Frequency (%)

Unknown

207 38.3%)

Chlorpyrifos

131 (24.2%)

Phorate

38

(7%)

Quinolphos

37

(6.8%)

Monocrotophos

29

(5.4%)

Carbamate

20

(3.7%)

Methyl parathion

20

(3.7%)

Dimethoate

18

(3.3%)

Profenophos

15

(2.8%)

Triazophos

14

(2.6%)

Malathion

7

(1.3%)

Dichlorophos

3

(0.6%)

Parathion

2

(0.4%)

Total

541 (100%)

Type of Admission

Most of the study subjects were cases referred from the local hospital 440 (81.3%) in whom, gastric lavage
was given and was on treatment with ATR and PAM 109 (20.1%) following were patients who are directly
admitted to the study hospital 101 (18.7%).
Table 4. Categories of admission to the emergency unit.
Type of Admission

Frequency (%)

Direct admission

101 (18.7%)

Referred , No treatment

50 (9.2%)

Referred , Intubated

49 (9.1%)

Referred , Gastric Lavage

60 (11.1%)

Referred, ATR Alone

33 (6.1%)

Referred ,Stomach wash + ATR

92 (17%)

Referred, ATR+ PAM

40 (7.4%)

Referred, Gastric Lavage + ATR+ PAM

109 (20.1%)

Referred, ATR+ PAM + GPR

7 (1.3%)

Total

541 (100%)
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V.

Physical examination of patients

Of the 541 patients, 467(86.3%) patients were conscious, 345(63.8%) patients were cooperative, 336
(62.1%) were oriented while 59 (10.9%) were found to be febrile.
Table 5. Physical examination.
Physical Examination
Conscious
 Yes
 No
Cooperative
 Yes
 No
Oriented
 Yes
 No
Febrile
 Yes
 No
VI.

Frequency (%)
467 (86.3%)
74 (13.7%)
345 (63.8%)
196 (36.2%)
336 (62.1%)
205 (37.9%)
59 (10.9%)
482 (89%)

Clinical Characteristics of OP poisoning.

The clinical presentation of organophosphate poisoning mainly included altered sensorium 111 (20.5%),
fasciculation 116 (21.4%), increased secretions 124 (22.7%) and shortness of breath 61 (11.3%). Further, 34
(6.3%) patients were found to have seizures and 27 (5%) were found to be in the coma state on admission.
Table 6. Clinical Presentation of OP poisoning patients.
Clinical Features
Mydriasis
Miosis
Restlessness
Agitation
Altered Sensorium
Fasciculation
Seizure
Coma
Shortness Of Breath
Increased Secretions
Bradycardia
Tachycardia
Sialorrhea
Vomiting
Diarrhoea
Abdominal Pain
Urinary Incontinence
Diaphoresis
Lacrimation

Frequency (%)
432 (79.9%)
16 (3%)
277 (51.2%)
12 (2.2%)
111 (20.5%)
116 (21.4%)
34 (6.3%)
27 (5%)
61 (11.3%)
124 (22.7%)
43 (7.9%)
78 (14.4%)
31 (5.7%)
94 (17.4%)
38 (7.8%)
17 (3.1%)
13 (2.4%)
43 (7.9%)
26 (4.8%)
16

VII.

Categorization of the treatment patterns.

Patients admitted with OP poisoning were grouped into one of the four treatment categories.
The four treatment groups were:
1) ATR alone treatment group: This group consisted of 165 (30.5%) of subjects treated with ATR alone.
2) ATR and PAM treatment group: Patients of this group 223 (41.22%) were treated with both ATR and
PAM.
3) ATR and GPR treatment group: Patients of this group 40 (7.39%) were treated with both ATR and
GPR.
4) ATR, PAM and GPR: Treatment in this group included all the three drugs. A total of 113 (20.89%) of
the patients were treated with this pattern.

Fig 4. Type of the treatment patterns.
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VIII.

Assessment of outcomes in various treatment patterns.
1) Primary outcomes:
Primary outcomes of various treatment regimen were assessed in terms of patients condition at
discharge (improved or unimproved). It was observed that the patients treated with ATR and PAM has
better improvement 167 (74.9%) than the patients treated with other regimen. The patient group treated
with ATR, PAM & GPR had the least improvement 64 (56.6).
The unimproved category includes the patients discharged against medical advice and expired patients.
Table 7. Primary outcomes in various treatment regimens.
Treatment Pattern

Improved
Unimproved

ATR
Alone
N=165
115 (69.7%)
50 (30.3%)

ATR+
PAM
N=223
167 (74.9%)
56 (25.1%)

ATR+
GPR
N=40
29 (72.5%)
11 (27.5%)

ATR+
PAM + GPR
N=113
64 (56.6%)
49 (43.4%)




32 (19.4%)
18 (10.9%)

34 (15.2%)
22 (9.9%)

9 (22.5%)
2 (5%)

28 (24.8%)
21 (18.6%)

Primary Outcomes

DAMA
Death

Fig 5. The outcome with various treatment regimens.
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2) Secondary Outcomes:
The secondary outcome of different treatment regimen was assessed in terms of intubation, mean
hospitalisation days, mean ICU days, mean days on ventilator, and percentage of development of
secondary complications. Mean hospitalisation days was higher in the group treated with ATR + PAM +
GPR whereas the group treated with ATR + PAM had the least days of ICU, ventilator days and
development of complications. The group with ATR & GPR was observed to have the highest incidence
of secondary complications.
Table 8. Secondary outcomes in various treatment regimens.
Treatment Pattern
Secondary Outcomes

Intubation
Mean Hospitalisation ±
SD
Mean ICU duration ±
SD
Mean Ventilator
duration ± SD
Secondary
complications

ATR
Alone

ATR+
PAM

ATR+
GPR

ATR+
PAM + GPR
N=113

N=165
75 (45.5%)
12.56 ± 8.58

N=223
65 (29.1%)
11.61 ± 7.25

N=40
23 (57.5%)
13.6 ± 8.00

63 (55.8%)
14.21 ± 9.87

9.28 ± 6.20

8.97 ± 5.85

11.36 ± 6.54

11.29 ± 7.68

8.85 ± 6.76

8.37 ± 7.11

11.12 ± 4.72

9.97 ± 6.85

73 (44.2%)

67 (30%)

26 (65%)

64(56.6%)

The total ICU days & days of ventilation were analysed using Kruskal-Wallis test and Mann-Whitney’s test
to assess the effectiveness of various treatment patterns. The results of Kruskal-Wallis test revealed that the
median ICU days and days of ventilation varied significantly (at p = 0.009, p = 0.021) respectively.
Table 9. Median, (Q1, Q3) values of ICU days & days of mechanical ventilation across various
treatment regimens.
Treatment pattern
ICU days
Median ( Q1, Q3 )
p value
ATRAlone
8 (5, 12)
p = 0.009
ATR+ PAM
8 (5, 11)
ATR+ GPR
10 (6, 15)
ATR+ PAM + GPR
10 (6, 15)
Treatment pattern
Days of mechanical ventilation
Median ( Q1, Q3 )
p value
ATRAlone
7 (3, 13)
p = 0.021
ATR+ PAM
7 (3, 11)
ATR+ GPR
11(7, 14)
ATR+ PAM + GPR
9 (5,13)
* Data was analysed by Kruskal-Wallis test.
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Mann-Whitney’s test revealed a significant difference (p = 0.004) in ICU days between patients
treated with ATR & PAM versus ATR, PAM & GPR.



Mann-Whitney’s test revealed a significant difference (p = 0.003) in days of ventilation between
patients treated with ATR & PAM versus ATR & GPR.

3) ATR utilisation among various treatment regimens:
ATR remains the mainstay in the treatment of OP poisoning. It was present in all the four treatment
patterns of comparison and was administered to all the patients presented with OP poisoning. The mean
and median ATR dose was found to be higher in the group treated with ATR, PAM & GPR.
Table 10. Mean ± SD, Median and (Q1, Q3) values of ATR utilised across various treatment
regimens.
Treatment Pattern
ATR
ATR+
ATR+
ATR+
Total ATR
Alone
PAM
GPR
PAM + GPR
N=113
N=165
N=223
N=40
Mean ATR
1726.48
2771.31
2364.24
2841.76
± SD
± 4289.49
± 6564.02
± 3961.72
± 4392.66
Median ATR
( Q1, Q3)

430.6
(143.08, 1070.00)

512.2
(180.6, 1493.1)

713.95
(114.73, 3271.6)

1099.5
(354.95, 2846.85)

The total ATR utilised was analysed using Kruskal-Wallis test and Mann-Whitney’s test to assess the variation
of ATR usage across the treatment patterns. The results of Kruskal-Wallis test revealed that the median of
total ATR utilised varied significantly at p < 0.001.
Table 11. Median (Q1, Q3) values of total ATR utilised among various treatment patterns.
Treatment

pattern

ATR Alone
ATR+ PAM
ATR+ GPR
ATR+ PAM + GPR

Total ATR
Median ( Q1, Q3)
430.60
(143.08, 1070.00)
512.20
(180.60, 1493.10)
713.95
(114.73, 3271.60)
1099.50
(354.95, 2846.85)

p value

p < 0.001

* Data was analysed by Kruskal-Wallis test.
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Mann-Whitney’s test revealed a significant difference (p < 0.001) in total ATR administered between
patient groups treated with ATR alone versus ATR, PAM & GPR and ATR & PAM versus ATR, PAM
& GPR.

The results of Spearman’s rho test revealed a mild association (correlation coefficient = 0.488) exists to the
total ATR administered to the patient with the increased days of hospitalisation.

Fig 6. Scatter plot of the total ATR usage with days of hospitalisation.
Intermittent ATR dosing pattern:
Among the study population, 24.4% were administered with intermittent ATRdosing with ampoules apart
from the normal ATR infusion.

Fig 7. Intermittent ATR dosing in the subject population.
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The results of cross-tabulation revealed that the subject population which developed secondary
complications were followed by the trend of intermittent ATR dosing.



The use of intermittent ATR dosing was not found to be significant on the overall outcome of the
patient (p = 0.065).

Table 12. Frequency of secondary complication and primary outcomes in patients with intermittent
ATR dosing.
Intermittent
Secondary
Total
Primary Outcome
Total
ATR Dosing

Complications
Yes

Yes

73 (55.3%)

No
59 (44.7%)

132

improved

unimproved

83 (62.9%)

49 (37.1%)

(100%)
No

157 (38.4%) 252 (61.6%)

409

(24.4%)
292 (71.4%) 117 (28.6%)

(75.6%)
Total

230 (42.5%) 311 (57.5%)

541

= 0.001

409
(75.6%)

375 (69.3%) 166 (30.7%)

(100%)
p value

132

541
(100%)

0.065

*Cross tabulation and Chi-Square analysis.
4) Secondary Complications:
The impact of 4 different regimens used in the management of OP poisoning was compared to the
secondary complications as shown in Table 13. We observed that all secondary complications were
comparatively less ATR+PAM group when compared to other treatment regimens.
The details are depicted in Table 13.
Table 13. Incidence of complications in various treatment groups.
Incidence

Intermediate Syndrome
Sepsis
Aspirational Pneumonia
Ventilator Associated
Pneumonia
Acute Renal Injury
Tracheostomy
Cardiac Arrest
Hypoxic Ischemic
Encephalopathy

ATR
Alone

Treatment pattern
ATR+
ATR+
PAM
GPR

ATR+
PAM + GPR
N=113

N=165
15 (9.1%)
16 (9.7%)
16 (9.7%)
25 (15.2%)

N=223
9 (4.0%)
9 (4.0%)
35 (15.7%)
13 (5.8%)

N=40
7 (17.5%)
4 (10.0%)
10 (25%)
13 (32.5%)

10 (8.8%)
16 (14.2%)
29 (25.7%)
19 (16.8%)

7 (4.2%)
28 (17.0%)
23 (13.9%)
16 (9.7%)

4 (1.8%)
10 (4.5%)
23 (10.3%)
6 (2.7%)

2 (5.0%)
10 (25.0%)
5 (12.5%)
2 (5.0%)

4 (3.5%)
13 (11.5%)
20 (17.7%)
4 (3.5%)
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The median of the quantity of poison ingested was higher in the group presented with secondary
complications to the group presented without secondary complications and the value was found to
be significant (p = 0.01).



The median of pseudocholinesterase levels was lower in the group presented with complications
to the group without complications and the value was found to be significant (p = 0.001).

Table 14. Median, (Q1, Q3) values of group with complications to the quantity of poison ingested
and pseudocholinesterase levels.
Secondary

Quantity Ingested

Pseudocholinesterase

Complications

N = 206

N = 540

Median ( Q1, Q3 )

Median ( Q1, Q3 )

Yes

No

Yes

100

Yes

216

74

(50, 200)

229

(136.5, 1587.0)

No

60

No

289

132

(30, 150)

311

(167.0, 3453.0)

p value

= 0.01

< 0.001

*Mann-Whitney’s comparison test



The median of the group with secondary complication has increased days of ICU than the group
without complications with a significant value of p < 0.001.



The median of the group with complications has increased days of mechanical ventilation to the
group without complications (p < 0.001).

Table 15. Median, (Q1, Q3) values of group with complications to days of mechanical ventilation
and days in ICU.
Secondary

Days of Mechanical

Complications

Ventilation

Days in ICU

Median ( Q1, Q3 )
Yes

No

Median ( Q1, Q3 )

Yes

8.5

Yes

11

200

(5, 13)

223

(6, 16)

No

5

No

7 (5, 10)

60

(3,10)

294

p value

< 0.001

< 0.001

*Mann-Whitney’s comparison test
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IX.

Comparison of the group treated with ATR alone versus ATR and GPR.
In the study population of 541, 165 patients received only ATR and 40 patients received ATR and
GPR combination.

Treatment Pattern
Atropine +
Glycopyrrolate
40 (19.51%)

Atropine Alone
Atropine + Glycopyrrolate

Atropine Alone
165 (80.49%)

Fig 8. Patients with ATR alone and ATR+ GPR treatment.
The outcome of these two groups was analysed in terms of primary and secondary outcomes. The primary
outcome included the percentage of improved, and percentage of unimproved. Secondary outcome included
days of hospitalization, days in ICU, days of ventilation, the incidence of intermediate syndrome and
development of secondary complications.
Outcome analysis of these groups revealed that there was no significant difference in the primary or secondary
outcomes except for, development of secondary complications (p = 0.018).
Table 16. Frequencies of primary outcomes & secondary complication in the treatment group of ATR
alone and ATR + GPR.
Primary Outcome

ATR

ATR+ GPR

Total

115 (69.7%)

29 (72.5%)

144 (70.2)

p value

Outcome


Improved



Unimproved 50 (30.3%)

11 (27.5%)

61 (29.8)

165 (100%)

40 (100%)

205 (100%)

Total

0.728

Secondary
Complication


Yes

73 (44.2%)

26 (65%)

99 (48.3%)



No

92 (55.8%)

14 (35%)

106 (51.7%)

165 (100%)

40 (100%)

205 (100%)

Total

0.018

*Cross tabulation and Chi-Square analysis.
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Table 17. Comparison of Median, (Q1, Q3) values in treatment groups of ATR alone & ATR+ GPR
with secondary outcomes.
Secondary

Days of

Outcomes

hospitalisation

ATR

Median

Median

( Q1, Q3 )

( Q1, Q3 )

( Q1, Q3 )

165

11

159

(8, 15)
40

8

86

7

(5, 12)

11

39

(7,19)

GPR
p value

Days on ventilation

Median

alone
ATR +

Days in ICU

(3, 13)

10

25

11

(6, 15)

= 0.554

(7, 14)

0.059

0.022

*Mann-Whitney’s comparison test

The GPR usage was compared with the development of aspirational pneumonia and ventilatorassociated pneumonia. There was a statistically significant increase in the incidence of ASP and
VAP with GPR usage with p = 0.009 & p = 0.011 respectively.

Table 18. Frequency of aspirational pneumonia and ventilator associated pneumonia in the group
treated with ATR + GPR.

GPR

Yes

No

Total

p value

Aspirational

Ventilator

Pneumonia

Associated Pneumonia

Yes

No

Yes

No

10

30

13

27

(25%)

(75%)

(32.5%)

(67.5%)

16

149

25

140

(9.67%)

(90.30%)

(15.15%)

(84.85%)

26

179

38

167

(12.69%)

(87.31%)

(18.54%)

(81.46%)

0.009

Total

40 (100%)

165 (100%)

205 (100%)

0.011

*Cross tabulation and Chi-Square analysis.
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Discussion
Organophosphate poisoning is one of the major global health hazards. There is an increase in the incidence of
self-harm with the use of OP poison in the developing nations. Our study included 541 patients presented to
the emergency unit with the consumption of OP poison.
532 (98.3%) patients have consumed poison with an intention of self-harm. This was in agreement with a
study in Karnataka by Banday et al.,(8) The mean age of subjects in our study was found to be 38.6 ± 15.61
years. A similar study by Coskun et al., found the mean age of the subjects to be 39 ± 16.(9) Gender wise
distribution showed male predominance 380 (70.2%) which can be correlated to a study by Kailas et al.,(10)
However a study by Chhetri et al., and Adinew et al., has shown female predominance with (60%) females
in their study population.(11)(12)
The incidence of poisoning was higher in daily wagers (28.1%) followed by agriculturalists (24.6%) is similar
to a study by Selvaraj et al., in Tamil Nadu with farmers and daily wagers comprised the major victims of OP
poisoning.(13) Psychiatric illness could be a driving force for the consumption of OP poison. In our study we
observed 79 (14.6%) subjects who consumed poison to have a psychiatric illness, Literature also reveals
psychiatric illness could be one of the possible causes of acute OP poisoning as reported by Khalaf AlMutairi
et al., in Saudi Arabian population where 10.98% of study population was suffering from psychiatric illness.(14)
Among different OP compounds Chlorpyrifos was the most consumed OP poison with 131 (24.2%) subject.
Similar results were seen in studies by Eddleston et al., and by Shahmy S et al., Since, chlorpyrifos is most
commonly available and widely utilised pesticide in both India and Srilanka hence probability of poisoning
by this compound is high.(15)(16)
Clinical presentation of the patients included restlessness (51.2%), increased secretions (22.7%),
fasciculations (21.4%) and altered sensorium (20.5%) to be most common. These clinical manifestations were
revealed to be similar in studies by Sungur et al., and Ranjeet etal.,.(17)(18)
In our study we observed 4 different treatment combinations used in the management of OP poisoning viz
Category1. ATR alone, category 2. ATR + PAM, category 3. ATR+ GPR and category 4 ATR + PAM + GPR.
However, most of the literature compared either ATR&PAM or ATR along with GPR. In our study we
observed that addition of PAM was found to be beneficial in terms of recovery rate in ATR&PAM group
compared to that of other categories. (79.9%), he secondary outcome was found to be better in ATR and PAM
group, we also observed that the utilisation of ATR is reduced in ATR and PAM group compared to group
with ATR+ PAM+ GPR. A study by Jokanovic et al., and Baloch et al., suggested the group with the usage
of PAM + ATR had lower mortality in comparison with the treatment of ATR alone.(19)(20) Although, a study
by Raja et al., interpreted no statistical change in the days of ICU and hospitalisation which was found to hold
true even in our study.(21) However, sharp dissent was observed in studies by Eddleston et al., Sungur et al.,
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Banerjee et al. Kamal et al., stating increased mortality in subjects administered with ATR + PAM and proved
better efficacy with treatment with ATR alone.(3)(17)(22)(23)
The outcome is mainly affected by poison load, initial treatment received and other comorbidities so, it is
important to consider all the factors before initiating the treatment. Literature suggests that addition of GPR
will help in better quality of treatment in OP poisoning.(24) However, our study is not able to provide any
insights with respect to better recovery rate and secondary complications in ATR and GPR similar to studies
by Bhandarkar et al., and Anju N etal.,.(25)(26)
We observed increased utilisation of ATR has a mild correlation to the longer duration of hospitalisation. This
might be probably due to ATR toxicity which leads to longer hospitalisation in the patient population.
Secondary complications has been compared with different dosage regimens to understand any influence of
the treatment on their development. We observed intermittent dosing is statistically associated with
development of secondary complication this is probably due to lower plasma concentration of atropine below
therapeutic window. A similar study by Kumaraswamy RC et al., found that the pattern of intermittent atropine
dosing increases the incidence of secondary complications.(27)
Among the treatment patterns, ATR and PAM had the least incidence of secondary complication since atropine
acts by blocking the action of acetylcholine as muscarinic receptors and PAM by reactivation of
cholinesterase.
These both mechanisms help in decreasing the cholinergic toxicity, so complications such as intermediate
syndromes and aspirational pneumonia can be controlled better.
Incidence of secondary complications correlates to the quantity of poison ingested, pseudocholinesterase
levels, days of mechanical ventilation and days in ICU. We observed a statistical correlation of the above
parameters in our study.
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LIMITATIONS
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LIMITATIONS


The information on poison type, pre-hospitalisation period, treatment at local hospital were not
available as it was a retrospective study.



Plasma acetylcholinesterase levels were not available.



Series pseudocholinesterase changes were not available.



The blood levels of toxins were not collected.



APACHE Scoring and GCS Scoring were not done for all the patients.



The different arms of treatment pattern did not have equal representation of patients.



Follow up was not done, hence development of delayed complications were not documented.
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CONCLUSION

Pesticide self-poisoning is a major health hazard in India mostly affecting agriculturalists and daily wagers.
Suicidal deaths were the most common reason for poisoning in the southern part of India. Majority of patients
were males belonging to reproductive age.
ATR is the common antidote used for the management of OP poisoning. Treatment analysis revealed addition
of PAM to ATR had better recovery rate in our study population. However, addition of GPR was not found
to have any beneficial effects. Dosing of ATR can influence the development of secondary complication.
Development of secondary complication is one of the most common outcome of delayed hospitalization and
is significantly correlated to quantity of poison ingested, pseudocholinesterase level, days on ventilation and
days in ICU.

.
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FUTURE DIRECTIONS:



A prospective study on comparison between different treatment regimens would yield better result.



Blood levels of Toxins, APACHE scoring can help in studying the effects of treatment on patients.



Studies regarding individual compound may give better results on treatment modalities.
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